- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/18 - Bridged systems
Patent holdings for IPC class C07D 471/18
Total number of patents in this class: 507
10-year publication summary
|
30
|
43
|
37
|
26
|
47
|
31
|
44
|
43
|
37
|
26
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4898 |
39 |
| Janssen Pharmaceutica N.V. | 3392 |
32 |
| Gilead Sciences, Inc. | 2036 |
28 |
| Sanofi | 4055 |
15 |
| Rigel Pharmaceuticals, Inc. | 539 |
13 |
| Pathios Therapeutics Limited | 25 |
13 |
| Abbott Laboratories | 2399 |
11 |
| Purdue Pharma L.P. | 499 |
9 |
| Lumiphore, Inc. | 36 |
8 |
| Centre National de La Recherche Scientifique | 10418 |
7 |
| Guerbet | 203 |
7 |
| Genentech, Inc. | 3976 |
6 |
| Universite de Bretagne Occidentale | 109 |
6 |
| Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | 23 |
5 |
| Teva Pharmaceuticals USA, Inc. | 894 |
5 |
| The University of Bristol | 250 |
5 |
| PH Health Limited | 28 |
5 |
| Novartis AG | 10849 |
4 |
| Merck Patent GmbH | 5831 |
4 |
| Aicuris GmbH & Co. KG | 71 |
4 |
| Other owners | 281 |